Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 19, 2008 Brian Lawler	Roche to Amgen: We Surrender Roche gives in to a judge's recommendation that it pay a higher royalty to Amgen on sales of its anemia drug Mircera.
The Motley Fool March 28, 2008 Brian Lawler	Amgen and Roche Still Duking It Out Amgen threatens to sue Roche for damages.
The Motley Fool October 3, 2008 Brian Orelli	Amgen Draws Blood in Anemia-Drug War The pharmaceutical fights off rival Roche.
The Motley Fool May 14, 2007 Mike Havrilla	A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs.
The Motley Fool October 29, 2007 Brian Lawler	Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader.
The Motley Fool March 25, 2010 Brian Orelli	More Than $5.3 Billion in Revenue Under Attack After dealing with the FDA, Amgen and J&J now have to deal with the Centers for Medicare & Medicaid Services.
The Motley Fool September 6, 2007 Brian Lawler	Amgen's Congressional Helpers Lawmakers push to ease restrictions on anemia compounds from Amgen and Johnson & Johnson. Investors, take note.
The Motley Fool August 26, 2009 Brian Orelli	Amgen Falls Back on the Future Instead of the TREAT trial for Aranesp, Amgen's new cherry is Prolia's potential to treat cancer patients, for which Amgen could get marketing approval next year.
The Motley Fool January 7, 2010 Brian Orelli	Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA.
The Motley Fool October 19, 2010 Brian Orelli	When the Status Quo Is a Big Win The lack of an FDA rejection will do just fine. Amgen and Johnson & Johnson seemed to get through the FDA advisory panel process without much problem yesterday.
The Motley Fool December 10, 2007 Brian Lawler	Amgen Under Review The FDA plans another debate about an Amgen top drug.
The Motley Fool August 9, 2010 Luke Timmerman	Affymax Lives to Fight Another Day Affymax takes on Amgen with its anemia drug.
The Motley Fool April 28, 2008 Brian Lawler	Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings.
The Motley Fool January 31, 2008 Brian Lawler	Don't Forget Roche Roche, the largest biopharma, by market capitalization, had a terrific 2007. Since it is not publicly listed on the major U.S. stock exchanges, the company never gets its fair share of attention.
The Motley Fool October 24, 2008 Brian Orelli	Amgen's Back Shares of Amgen are up 40% from their lows in March. And for good reason.
The Motley Fool January 25, 2008 Brian Lawler	Amgen: Punched Out or Still Fighting? Amgen manages to pull off a 3.5% increase in revenue for 2007, even with sales of its anemia franchise drugs Aranesp and Epogen down a combined 17% year over year in the fourth quarter.
The Motley Fool September 10, 2007 Brian Lawler	Get a Glimpse of Amgen's Future Investors will want to pay attention to an FDA advisory panel meeting discussing new labeling recommendations for Amgen's anemia medications. The two drugs represented 44% of the pharmaceutical company's second-quarter revenue.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool January 26, 2010 Brian Orelli	Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010.
The Motley Fool October 25, 2011 Brian Orelli	Anemic Growth in All the Right Places Amgen's anemia drugs decline, but that's not its future anyway.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Red and White Results at Amgen At current levels, this biotech titan could be worth a further look from investors.
The Motley Fool July 21, 2005 Tom Taulli	Amgen One-Ups Genentech New Medicare regulations look to be harmless, and as a result, Amgen is off to the races. Still, investing in biotech is always dicey.
The Motley Fool July 30, 2007 Brian Lawler	Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool September 28, 2006 Brian Lawler	Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool July 30, 2010 Brian Orelli	On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually.
BusinessWeek March 22, 2004 Arlene Weintraub	Amgen Opens The Secret Curtain The biotech leader will host analysts and investors to drum up excitement for its pipeline -- and its stock. Will it work?
The Motley Fool October 26, 2010 Brian Orelli	Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth.
BusinessWeek May 15, 2006 Arlene Weintraub	Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.
BusinessWeek June 4, 2007 Gene G. Marcial	Amgen Believers There has been a deluge of bad news at biotech Amgen, whose stock has tumbled.
The Motley Fool October 22, 2009 Brian Orelli	Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia.
The Motley Fool July 12, 2004 Ben McClure	Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good.
The Motley Fool May 27, 2009 Brian Orelli	A Partnership of the Heart Amgen, the large biotech company, exercises its right to license Cytokinetic's cardiac contractility program, including heart failure drug CK-1827452.
The Motley Fool January 27, 2009 Brian Orelli	Amgen's Anemic Again 2009 won't be stellar, but the future looks better.
The Motley Fool March 17, 2008 Brian Lawler	The Panelling on Amgen's Walls One FDA panel ruling is a win, another is much less upsetting than investors feared.
The Motley Fool August 27, 2010 Brian Orelli	Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen.
The Motley Fool December 8, 2011 Luke Timmerman	Affymax Passes FDA Panel Scrutiny, Looks to Challenge Amgen Anemia Drug Many investors wrote off Affymax in June 2010, but was that premature?
The Motley Fool February 27, 2008 Brian Orelli	Everyone's Picking on Anemia Drugs A new study in The Journal of the American Medical Association is adding fuel to the fire about Amgen's and Johnson & Johnson's anemia drugs. Should investors worry?
The Motley Fool June 2, 2010 Brian Orelli	Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market.
BusinessWeek April 23, 2007 Alex Halperin	Vioxx Casts A Long, Long Shadow More than two years after Merck & Co. pulled its Vioxx painkiller from shelves over heart attack and stroke risks, the Food & Drug Administration is still skittish about the safety of drugs currently on the market and those coming up for review.
The Motley Fool April 24, 2007 Brian Lawler	Amgen On Sale? Biotech giant Amgen announces first-quarter financial results. Longer-term investors willing to wait for Amgen's drug pipeline to mature may be getting their chance to own a proven Ferrari at Ford prices.
The Motley Fool February 9, 2010 Brian Orelli	Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status.
The Motley Fool October 17, 2007 Brian Orelli	J&J Puts Band-Aid on the Quarter Investors, Johnson & Johnson's earnings report reads like a one-hit wonder's second album. It goes from good to bad in the blink of an eye -- or in this case, a paragraph or so.
The Motley Fool October 20, 2005 Brian Gorman	Amgen's Drive to Diversify The drugmaker pulled in impressive results with its current portfolio, but a drug in late-stage testing could make the company even more attractive to investors.
The Motley Fool July 28, 2009 Brian Orelli	Amgen Secures Its Future Earnings and a marketing partnership -- oh my.
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.
The Motley Fool November 19, 2010 Brian Orelli	One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales.
The Motley Fool January 29, 2007 Brian Lawler	No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap.
The Motley Fool May 4, 2007 Mike Havrilla	Taking It to the Affymax Positive clinical data for a potential anemia treatment has the drugmaker's stock on the rise.